Topic · Bone health and treatments
Most cited papers in Bone health and treatments
What are the most cited papers in Bone health and treatments?
The most cited paper in Bone health and treatments is "Osteoclast differentiation and activation" (William J. Boyle, W. Scott Simonet, David L. Lacey, 2003), with 6,707 citations. Next come "Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation" (5,491) and "Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy" (4,645).
Showing 50 of 100 papers. Every paper with more than 1,303 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Osteoclast differentiation and activation William J. Boyle, W. Scott Simonet, David L. Lacey · Nature | May 2003 | 6,707 |
| 2 | Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation David L. Lacey et al. · Cell | Apr 1998 | 5,491 |
| 3 | Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy Howard I. Scher, Karim S. Fizazi, Fred Saad et al. · New England Journal of Medicine | 15 Aug 2012 | 4,645 |
| 4 | Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis Robert M. Neer, Claude D. Arnaud, José Zanchetta et al. · New England Journal of Medicine | 10 May 2001 | 4,604 |
| 5 | Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Hisataka Yasuda, Nobuyuki Shima, Nobuaki NAKAGAWA et al. · Proceedings of the National Academy of Sciences | 31 Mar 1998 | 4,281 |
| 6 | Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation Patricia F. Ducy, Rui Zhang, Valérie A. Geoffroy et al. · Cell | May 1997 | 4,278 |
| 7 | Clinician’s Guide to Prevention and Treatment of Osteoporosis Felicia Cosman, Suzanne M. Jan de Beur, Meryl Susan LeBoff et al. · Osteoporosis International | 14 Aug 2014 | 4,141 |
| 8 | Bone Resorption by Osteoclasts Steven L. Teitelbaum · Science | Sep 2000 | 4,011 |
| 9 | The diagnosis of osteoporosis John A. Professor Kanis, L. Joseph Melton, Claus Christiansen et al. · Journal of Bone and Mineral Research | Aug 1994 | 3,904 |
| 10 | Epidemiology and outcomes of osteoporotic fractures Steven Ron Cummings, L. Joseph Melton · The Lancet | May 2002 | 3,850 |
| 11 | The Novel Zinc Finger-Containing Transcription Factor Osterix Is Required for Osteoblast Differentiation and Bone Formation Kazuhisa Nakashima, Xin Zhou, Gary R. Kunkel et al. · Cell | 2002 | 3,643 |
| 12 | Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis Steven Ron Cummings, Javier San Martín, Michael R. McClung et al. · New England Journal of Medicine | 11 Aug 2009 | 3,503 |
| 13 | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Young‐Yun Kong, Hiroki Yoshida, Ildiko Sarosi et al. · Nature | 1999 | 3,385 |
| 14 | Studies on Prostatic Cancer: I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate Charles Huggins, Clarence V. Hodges · The Journal of Urology | Jul 2002 | 3,204 |
| 15 | de la Chapelle, A. Peter Beighton, Greta Beighton | 1997 | 3,167 |
| 16 | Enzalutamide in Metastatic Prostate Cancer before Chemotherapy Tomasz M. Beer et al. · New England Journal of Medicine | Jun 2014 | 3,076 |
| 17 | Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis Dennis M. Black et al. · New England Journal of Medicine | 3 May 2007 | 2,988 |
| 18 | American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update Salvatore L. Ruggiero, Thomas B. Dodson, John E Fantasia et al. · Journal of Oral and Maxillofacial Surgery | 5 May 2014 | 2,926 |
| 19 | Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development Florian Otto, Anders Thornell, Tessa Crompton et al. · Cell | May 1997 | 2,834 |
| 20 | Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy Charles J. Ryan et al. · New England Journal of Medicine | 10 Dec 2012 | 2,827 |
| 21 | Metastasis to bone: causes, consequences and therapeutic opportunities Gregory R. Mundy · Nature reviews. Cancer | Aug 2002 | 2,802 |
| 22 | Mechanisms of Bone Metastasis Garson David Roodman · New England Journal of Medicine | 14 Apr 2004 | 2,764 |
| 23 | Osteoporosis: now and the future Tilman D. Rachner, Sundeep Khosla, Lorenz Christian Hofbauer · The Lancet | 30 Mar 2011 | 2,713 |
| 24 | A multigenic program mediating breast cancer metastasis to bone Yibin Kang, Peter M. Siegel, Weiping Shu et al. · Cancer Cell | Jun 2003 | 2,627 |
| 25 | Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity Robert Edward Coleman · Clinical Cancer Research | 15 Oct 2006 | 2,508 |
| 26 | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Nathan Bucay, Ildiko Sarosi, Colin Robert Dunstan et al. · Genes & Development | May 1998 | 2,498 |
| 27 | Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis A Randomized Controlled Trial Steven T. Harris · JAMA | 13 Oct 1999 | 2,459 |
| 28 | Osteoporosis Juliet Elizabeth Compston, Michael R. McClung, William Donald Leslie · The Lancet | 2019 | 2,398 |
| 29 | Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer Karim S. Fizazi, NamPhuong Tran, Luis Enrique Fein et al. · New England Journal of Medicine | 4 Jun 2017 | 2,310 |
| 30 | Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis Uri A. Liberman, Stuart R. Weiss, Johann Bröll et al. · New England Journal of Medicine | 30 Nov 1995 | 2,304 |
| 31 | Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures Results From the Fracture Intervention Trial Steven R. Cummings · JAMA | 23 Dec 1998 | 2,292 |
| 32 | The amazing osteocyte Lynda Faye Bonewald · Journal of Bone and Mineral Research | 16 Dec 2010 | 2,285 |
| 33 | Diagnosis of osteoporosis and assessment of fracture risk John А. Kanis · The Lancet | Jun 2002 | 2,275 |
| 34 | Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families Tatsuo Suda, Naoyuki Takahashi, Nobuyuki Udagawa et al. · Endocrine Reviews | Jun 1999 | 2,275 |
| 35 | Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis* Stavros C. Manolagas · Endocrine Reviews | Apr 2000 | 2,238 |
| 36 | Osteosarcoma incidence and survival rates from 1973 to 2004 Lisa Mirabello, Rebecca J. Troisi, Sharon A. Savage · Cancer | 5 Feb 2009 | 2,215 |
| 37 | Normal Bone Anatomy and Physiology Bart Lyman Clarke · Clinical Journal of the American Society of Nephrology | Nov 2008 | 2,167 |
| 38 | Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein Guangbin Luo, Patricia F. Ducy, Marc D. McKee et al. · Nature | Mar 1997 | 2,125 |
| 39 | WNT signaling in bone homeostasis and disease: from human mutations to treatments Roland Baron, Michaela Kneissel · Nature Medicine | Feb 2013 | 2,113 |
| 40 | Bone Quality — The Material and Structural Basis of Bone Strength and Fragility Ego Seeman, Pierre Dominique Delmas · New England Journal of Medicine | 24 May 2006 | 2,086 |
| 41 | Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases Salvatore L. Ruggiero, Bhoomi Mehrotra, Tracey J. Rosenberg et al. · Journal of Oral and Maxillofacial Surgery | 23 Apr 2004 | 2,066 |
| 42 | Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells Rinaldo Florencio‐Silva, Gisela Rodrigues da Silva Sasso, Estela Sasso‐Cerri et al. · BioMed Research International | 2015 | 2,040 |
| 43 | Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture Kenneth W. Lyles, Cathleen S Colon-Emeric, Jay S Magaziner et al. · New England Journal of Medicine | 18 Sep 2007 | 2,008 |
| 44 | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Nicholas David James et al. · The Lancet | 21 Dec 2015 | 1,985 |
| 45 | Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Karim S. Fizazi, Michael Anthony Carducci, Matthew R. Smith et al. · The Lancet | 26 Feb 2011 | 1,981 |
| 46 | Cellular signaling by fibroblast growth factor receptors Veraragavan P. Eswarakumar, Irit Lax, Joseph Schlessinger · Cytokine & Growth Factor Reviews | 2 Feb 2005 | 1,948 |
| 47 | Metastatic bone disease: clinical features, pathophysiology and treatment strategies Robert Edward Coleman · Cancer Treatment Reviews | Jun 2001 | 1,942 |
| 48 | Effect of Risedronate on the Risk of Hip Fracture in Elderly Women Michael R. McClung, Piet Geusens, Paul D. Miller et al. · New England Journal of Medicine | Feb 2001 | 1,931 |
| 49 | Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients Lukas Bubendorf, S. Alain, Urs Wagner et al. · Human Pathology | May 2000 | 1,921 |
| 50 | European guidance for the diagnosis and management of osteoporosis in postmenopausal women John А. Kanis, Cyrus Cooper, René Rizzoli et al. · Osteoporosis International | 15 Oct 2018 | 1,898 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.